Impact on Healthcare Industry
Catheter related bloodstream infections (CRBSIs) have been a longtime challenge for hospitals and healthcare facilities. These infections not only cause harm to patients but also result in increased costs, extended hospital stays and loss of revenue for providers. With rising cases of CRBSIs being reported across the country, it is becoming a serious issue affecting the healthcare industry.
Rising Infection Rates
Data from the Centers for Disease Control and Prevention shows that CRBSIs account for over 250,000 cases annually in the United States. This translates to around one infection for every 1,000 catheter days. Several studies have found the infection rates to be higher for patients in intensive care units who require central lines for extended periods. The frequency of CRBSIs has seen an upward trend over the past decade due to growing antibiotic resistance and increasing risk factors like aging population and complicated medical procedures. If left unaddressed, experts warn that the rates could continue climbing in the coming years.
Financial Burden on Hospitals
Treating patients with CRBSIS places a huge financial strain on hospitals. It is estimated that the excess costs associated with each infection ranges between $33,000 to $56,000. This includes additional antimicrobial use, invasive procedures for diagnosis and treatment, prolonged hospitalization and increased nursing care. Multiplying these costs by the large number of cases reported annually results in an economic burden of over $5 billion for US healthcare facilities. Some studies have also found that hospitals may lose up to $70,000 or more in reimbursements and penalties due to health care-associated infections.
Impact on Hospital Reimbursement
The rising CRBSI rates not only increase treatment expenses for hospitals but also affect their reimbursement. The Centers for Medicare and Medicaid Services have implemented various policies to reduce payment to hospitals that have high rates of certain avoidable healthcare-acquired conditions like central line-associated bloodstream infections. These non-payment penalties coupled with bundled payment models are putting more financial pressure on institutions. Many private payers have also adopted a similar approach by denying additional payments for treating infections acquired during hospital stay. This financial disincentive is forcing hospitals to invest more in infection control measures to curb CRBSIs.
Improving Prevention Strategies
To combat the growing problem of CRBSIs, healthcare facilities have stepped up prevention efforts through multifaceted strategies. This involves dedicated vascular access teams for line insertion and maintenance, use of antiseptic contaminated devices and maximal sterile barrier precautions during insertion. Hospitals are also focusing on staff education and adherence to evidence-based guidelines published by CDC for optimal catheter care and prompt removal of unnecessary lines. Some have implemented checklists, reminders and electronic surveillance tools to monitor compliance. While these measures have shown success in reducing CRBSI rates, sustained efforts are needed to further curb infections and their economic impact on the industry.
Investment in New Technologies
Beyond traditional prevention tactics, hospitals are investing in novel technologies to minimize the risk of CRBSIs. This includes sterile coated catheters that prevent bacterial colonization on the catheter surface as well as antimicrobial impregnated central venous catheters and connectors. Use of antimicrobial dressings, needleless systems and disinfectant caps also help maintain the sterility of invasive devices. More US hospitals are proactively adopting these advanced products, despite the higher upfront costs, to curb the growing economic burden in the long run. Researchers are also exploring technologies like intravenous robotics, medical imaging and big data analytics to further enhance prevention efforts.
Challenges Persist
Despite raising awareness and allocating more resources towards prevention, complete elimination of CRBSIs remains challenging. Areas like intensive care units dealing with high-risk patients still report significant infection rates. Limited durability of some novel technologies and lack of multi-drug resistant organism decontamination also impede progress. Ensuring consistent compliance to protocols among busy clinical staff remains an ongoing task. Restricted hospital budgets also deter rapid adoption of costly equipment. Regulatory agencies continue enhancing policies to incentivize quality improvement and assuage the financial impact of infections through value-based payment models. With collaborative efforts, it is hoped that CRBSI rates can be lowered substantially in the coming years saving both lives and healthcare dollars.
Get More Insights On Catheter Related Blood Stream Infections
The global Hospital Acquired Infection Control market is segmented by company, region (country), by Type, and by Application.
Players, stakeholders, and other participants in the global Hospital Acquired Infection Control market will be able to gain the upper hand as they use the report as a powerful resource.
The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by TypeDownload FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-hospital-acquired-infection-control-2021-725 Catheter-associated Urinary Tract Infections (CAUTIs)Surgical Site Infections (SSIs)Central Line-associated Bloodstream Infections (CLABSIs)Respiratory Infections Segment by Application Hospitals and ICUsOutpatient Care CentersLong-term Care Facilities (LTCFs) The Hospital Acquired Infection Control market is analysed and market size information is provided by regions (countries).
Segment by Application, the Hospital Acquired Infection Control market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company PfizerRocheMerckJohnson & JohnsonAbottBayerBDKimberly-ClarkNordionCepheidGet the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-hospital-acquired-infection-control-2021-725Table of content1 Hospital Acquired Infection Control Market Overview1.1 Hospital Acquired Infection Control Product Scope1.2 Hospital Acquired Infection Control Segment by Type1.2.1 Global Hospital Acquired Infection Control Sales by Type (2016 & 2021 & 2027)1.2.2 Catheter-associated Urinary Tract Infections (CAUTIs)1.2.3 Surgical Site Infections (SSIs)1.2.4 Central Line-associated Bloodstream Infections (CLABSIs)1.2.5 Respiratory Infections1.3 Hospital Acquired Infection Control Segment by Application1.3.1 Global Hospital Acquired Infection Control Sales Comparison by Application (2016 & 2021 & 2027)1.3.2 Hospitals and ICUs1.3.3 Outpatient Care Centers1.3.4 Long-term Care Facilities (LTCFs)1.4 Hospital Acquired Infection Control Market Estimates and Forecasts (2016-2027)1.4.1 Global Hospital Acquired Infection Control Market Size in Value Growth Rate (2016-2027)1.4.2 Global Hospital Acquired Infection Control Market Size in Volume Growth Rate (2016-2027)1.4.3 Global Hospital Acquired Infection Control Price Trends (2016-2027)2 Hospital Acquired Infection Control Estimates and Forecasts by Region2.1 Global Hospital Acquired Infection Control Market Size by Region: 2016 VS 2021 VS 20272.2 Global Hospital Acquired Infection Control Retrospective Market Scenario by Region (2016-2021)2.2.1 Global Hospital Acquired Infection ConCONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
Rising number of sepsis cases and high cost of treatment drives the blood culture test market.Blood culture is a type of test to check for external objects, such as yeast, bacteria and other micro-organisms in your body may be an indication of a blood infection, or a disease recognized as bacteremia.
Bacteria that begin on your skin or in your urine, lungs, or gastrointestinal tract are prevalent causes of blood infection.Rising number of regulatory approvals and new product launches is the vital factor escalating the market growth, also rising geriatric population, increased prevalence of infectious diseases, rising demand for rapid diagnostic techniques, increased incidence of bloodstream infections and rising regulatory approvals and new product releases are the major factors among others driving the blood culture test market.
Moreover, emerging economies and rising identification of antibiotic-resistant microorganisms will further create new opportunities for blood culture test market in the forecasted period of 2021-2028.Get More Insight About the North America Blood Culture Test Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=north-america-blood-culture-test-marketHowever, increased cost of automated instruments, and lack of trained laboratory technicians are the major factors among others which will obstruct the market growth, while survival of players offering conventional blood culture products and survival of small players will further challenge the growth of blood culture test market in the forecast period mentioned above.This blood culture test market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.
The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.On the basis of method, the blood culture test market is segmented into automated blood culture and manual/conventional blood culture.Based on product, the blood culture test market is segmented into consumables, instruments, software and services.
Consumables have been further segmented into blood culture media, assay kits & reagents and blood culture accessories.
Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance.
